Fulltext

Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

Martin P 1 , Awan AA 2 , Berenguer MC 3 , Bruchfeld A 4 , Fabrizi F 5 , Goldberg DS 6 Show all authors , Jia J 7 , Kamar N 8 , Mohamed R 9 , Pessôa MG 10 , Pol S 11 , Sise ME 12 , Balk EM 13 , Gordon CE 14 , Adam G 13 , Cheung M 15 , Earley A 15 , Jadoul M 16

Affiliations 

  • 1 Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA. Electronic address: pmartin2@med.miami.edu
  • 2 Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
  • 3 Department of Gastroenterology, Hepatology Unit & Instituto de Investigación La Fe, Hospital Universitari i Politècnic La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Valencia, Spain; School of Medicine, University of Valencia, Valencia, Spain
  • 4 Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden; Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet, Stockholm, Sweden
  • 5 Division of Nephrology, Maggiore Hospital and Foundation IRCCC Cà Granda Ospedale Maggiore Policlinico, Milano, Italy
  • 6 Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA
  • 7 Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China; Beijing Key Laboratory of Transitional Medicine on Liver Cirrhosis, National Clinical Research Center for Digestive Diseases, Beijing, China
  • 8 Departments of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France; INFINITY- Inserm U1291-CNRS U5051, Toulouse, France; Université Paul Sabatier, Toulouse, France
  • 9 Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia
  • 10 Division of Clinical Gastroenterology and Hepatology, Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, Brazil
  • 11 Hepatology Department, Hopital Cochin, Université Paris Descartes, Paris, France
  • 12 Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
  • 13 Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, Rhode Island, USA
  • 14 Tufts Medical Center, Division of Nephrology, Boston, Massachusetts, USA
  • 15 Kidney Disease: Improving Global Outcomes (KDIGO), Brussels, Belgium
  • 16 Department of Nephrology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium. Electronic address: michel.jadoul@saintluc.uclouvain.be
Kidney Int, 2022 Dec;102(6):1228-1237.
PMID: 36411019 DOI: 10.1016/j.kint.2022.07.012

Abstract

Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy or with a kidney transplant. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2018, advances in HCV management, particularly in the field of antiviral therapy and treatment of HCV-associated glomerular diseases, coupled with increased usage of HCV-positive kidney grafts, have prompted a reexamination of the 2018 guideline. As a result, the Work Group performed a comprehensive review and revised the 2018 guidance. This Executive Summary highlights key aspects of the updated guideline recommendations for 3 chapters: Chapter 2: Treatment of HCV infection in patients with CKD; Chapter 4: Management of HCV-infected patients before and after kidney transplantation; and Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications